{"filing": {"accession": "0001493152-26-022895", "cik": "0001763950", "ticker": "LTRN", "company_name": "Lantern Pharma Inc.", "form_type": "424B5", "filing_type": "424B5", "filing_date": "2026-05-14", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226022895/0001493152-26-022895-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226022895/0001493152-26-022895-index.htm", "period_of_report": null}, "html_url": "/api/filings/000149315226022895/stream", "exhibits": [], "sections": [], "tables": [{"table_index": 2, "table_type": "financial", "caption": null, "header_text": "Per Share ofCommon StockPer Pre-FundedWarrantTotal"}, {"table_index": 6, "table_type": "exhibit_index", "caption": null, "header_text": "Page"}, {"table_index": 7, "table_type": "exhibit_index", "caption": null, "header_text": "ABOUT THIS PROSPECTUSii"}, {"table_index": 12, "table_type": "text", "caption": null, "header_text": "Common\n stock offered by us1,454,175\n shares of our common stock."}, {"table_index": 14, "table_type": "financial", "caption": null, "header_text": "Use\n of proceedsWe\n estimate that the net proceeds of this offering, after deducting placement agent fees and estimated offering expenses (and assuming\n no exercise of the purchase warrants), will be "}, {"table_index": 15, "table_type": "text", "caption": null, "header_text": "\u25cf1,502,035\n shares of common stock issuable upon exercise of options outstanding as of March 31, 2026, which have a weighted average exercise\n price of $5.58 per share;"}, {"table_index": 18, "table_type": "financial", "caption": null, "header_text": "\u25cfactual\n or anticipated variations in our and our competitors\u2019 results of operations and financial condition;"}, {"table_index": 20, "table_type": "text", "caption": null, "header_text": "\u25cfthe\n timing and success of introductions of new technologies, therapeutic approaches, product candidates and product marketing applications\n by us or our competitors or any other change in the compet"}, {"table_index": 22, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional\n funding;"}, {"table_index": 25, "table_type": "text", "caption": null, "header_text": "Offering price per share of common stock$2.06"}, {"table_index": 26, "table_type": "text", "caption": null, "header_text": "\u25cf1,296,126\n shares of common stock issuable upon exercise of options outstanding as of December 31, 2025, which have a weighted average exercise\n price of $ 5.58 per share;"}, {"table_index": 30, "table_type": "financial", "caption": null, "header_text": "Per Share ofCommon StockPer Pre-FundedWarrantTotal"}, {"table_index": 32, "table_type": "text", "caption": null, "header_text": "\u25cfmay\n not engage in any stabilization activity in connection with our securities; and"}, {"table_index": 34, "table_type": "text", "caption": null, "header_text": "\u25cfour\n Annual Report onForm 10-Kfor the year ended December 31, 2025, which was filed with the SEC on March 30, 2026;"}, {"table_index": 41, "table_type": "exhibit_index", "caption": null, "header_text": "ABOUT THIS PROSPECTUSii"}, {"table_index": 54, "table_type": "text", "caption": null, "header_text": "\u25cfthe title and stated value;"}, {"table_index": 57, "table_type": "financial", "caption": null, "header_text": "\u25cfthe provisions for redemption\n or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;"}, {"table_index": 143, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n date of determining the security holders entitled to the rights distribution;"}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 29}